Prior Auth Required
01987 - 8. Kang C. Lumasiran: A Review in Primary Hyperoxaluria Type 1. Drugs. 2024 Jan 22. doi: 10.1007/s40265-023- -1. 3/2024
This procedure appears on the selected insurer prior authorization source.
Prior authorizationPrior Auth Required
Procedure / Service8. Kang C. Lumasiran: A Review in Primary Hyperoxaluria Type 1. Drugs. 2024 Jan 22. doi: 10.1007/s40265-023- -1. 3/2024
Procedure / Service Description
Pharmacy Policy - Policy/Procedure Name: Oxlumo (lumasiran) and Rivfloza (neodsiran) Control Number: 1350/20.000407 8. Kang C. Lumasiran: A Review in Primary Hyperoxaluria Type 1. Drugs. 2024 Jan 22. doi: 10.1007/s40265-023-01987-1. 3/2024 Epub ahead of print. Erratum in: Drugs. 2024 Mar 15;: PMID: 38252335. 9. Martin-Higueras C, Borghese L, Torres A, et al. Multicenter Long-Term Real World Data on Treatment With Lumasiran in 3/2024
Likely documents
- Confirm benefit details
- Submit clinical notes if requested by the plan
Next actions
- Confirm the current plan policy before submission.
- Use the insurer authorization workflow for this listed code.